The post discusses an experimental cancer treatment focusing on the neoadjuvant use of a combination of three immunotherapeutics: Ipilimumab (Ipi), Nivolumab (Nivo), and Relatlimab. This approach represents a novel application in the treatment of Glioblastoma Multiforme (GBM), although the combination of Ipi and Nivo is already established in other cancer types. The effectiveness and tolerability of such combinations remain under scrutiny, especially concerning potential side effects. The case of Richard Scolyer, an Australian pathologist diagnosed with GBM, serves as an example of this treatment's implications. Despite optimism surrounding the trial, the real-world efficacy and widespread applicability of this treatment are still uncertain, needing further investigation and time before any definitive conclusions can be made.